Oral pre‐exposure prophylaxis initiation, continuation and adherence among pregnant and postpartum women receiving antenatal and postnatal care: a systematic review
Journal of the International AIDS Society · 2025-09 · 28 (S5)
DOI: 10.1002/jia2.70035 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Journal of the International AIDS Society, online erschienen am 08.10.2025. Verfasst von Anke Rotsaert und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Public Health, Institute of Tropical Medicine, Antwerp, Belgium. Hauptthemen laut MEDLINE: Pre-Exposure Prophylaxis, HIV Infections, Anti-HIV Agents, Infectious Disease Transmission, Vertical. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Institute of Child Health and Human Development.
Abstract (Originalsprache)
Introduction
In 2023, one‐fourth of new HIV acquisitions in children globally resulted from vertical transmission following incident HIV during pregnancy or breastfeeding. Oral pre‐exposure prophylaxis (PrEP) with tenofovir disoproxil and emtricitabine is safe and effective in pregnancy and postpartum, with long‐acting options emerging. Integrating PrEP into antenatal and postnatal care (ANC/PNC) is a crucial person‐centred approach to prevent maternal HIV acquisition and vertical transmission. This review summarizes oral PrEP initiation, continuation and adherence among pregnant and postpartum women receiving ANC/PNC.
Methods
We systematically searched three databases for English‐language quantitative studies published between 1 January 2015 and 28 March 2024. Eligible studies focused on pregnant and/or postpartum women accessing PrEP through ANC/PNC, and reported on initiation (receipt of prescription or self‐reported use), continuation (persistent use over time) and/or adherence (self‐reported and/or objective).
Results
We identified 481 articles; 12 studies from Kenya, Lesotho, Malawi and South Africa met our inclusion criteria. Study heterogeneity (e.g. definitions used, population included, follow‐up time) precluded meta‐analysis. All studies enrolled pregnant women; three also enrolled postpartum women. Median gestational age at enrolment ranged from 20 to 26 weeks, and follow‐up periods from 1 month post‐enrolment to 12 months postpartum. Oral PrEP initiation ranged from 14% to 84%. Continuation at 3 months ranged from 22% to 90% and declined postpartum in all studies. Self‐reported adherence (daily use) ranged from 11% to 81% in the past 7 or 30 days at 1 month (four studies) and from 54% to 81% at 3 months (two studies). Objectively measured adherence ranged from 34% to 62% for detectable tenofovir or tenofovir diphosphate levels at 1 month (three studies). One Kenyan trial demonstrated that universal versus risk‐based offers of oral PrEP resulted in similar PrEP use and HIV incidence. Two‐way SMS communication (Kenya) and real‐time adherence biofeedback counselling using urine tenofovir testing (South Africa) enhanced PrEP continuation/adherence compared to standard‐of‐care.
Discussion
Integrating oral PrEP into ANC/PNC showed high initiation among pregnant/postpartum women; however, continuation and adherence were suboptimal.
Conclusions
Oral PrEP integration into ANC/PNC can reach pregnant/postpartum women. Maximizing its impact will require offering long‐acting PrEP, person‐centred interventions to support adherence/continued use and differentiated delivery responsive to women's needs. PROSPERO Number CRD42024513442
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Public Health, Institute of Tropical Medicine, Antwerp, Belgium.
- Centre for Community-Based Research, Human Sciences Research Council, Pietermaritzburg, South Africa.
- South African Research Ethics Training Initiative, University of KwaZulu-Natal Natal, Durban, South Africa.
- Department of Infectious Diseases, Geffen School of Medicine, University of California, Los Angeles, California, USA.
- Department of Epidemiology & Biostatistics, School of Public Health, University of Cape Town, Cape Town, South Africa.
ORCID-Profile: Anke Rotsaert, Zaynab Essack
Förderung
- National Institute of Child Health and Human Development
Zitieren
APA
Rotsaert, A., Essack, Z., Bosman, S., Davey, D. J., & Hensen, B. (2025). Oral pre‐exposure prophylaxis initiation, continuation and adherence among pregnant and postpartum women receiving antenatal and postnatal care: a systematic review. Journal of the International AIDS Society, 28(S5). https://doi.org/10.1002/jia2.70035
Vancouver
Rotsaert A, Essack Z, Bosman S, Davey DJ, Hensen B. Oral pre‐exposure prophylaxis initiation, continuation and adherence among pregnant and postpartum women receiving antenatal and postnatal care: a systematic review. Journal of the International AIDS Society. 2025;28(S5). doi:10.1002/jia2.70035
BibTeX
@article{Rotsaert2025,
author = {Rotsaert, Anke and Essack, Zaynab and Bosman, Shannon and Davey, Dvora Joseph and Hensen, Bernadette},
title = {Oral pre‐exposure prophylaxis initiation, continuation and adherence among pregnant and postpartum women receiving antenatal and postnatal care: a systematic review},
journal = {Journal of the International AIDS Society},
year = {2025},
volume = {28},
number = {S5},
doi = {10.1002/jia2.70035}
}
EUVIMED